For years Johnson & Johnson's consumer unit was an embarrassment to CEO Alex Gorsky. Instead of being able to point to its contribution to quarterly results, he instead found himself explaining recalls of key products like Tylenol and the unit's drag on earnings. But a turnaround is at hand, with the unit turning in 2.4% growth in sales in Q2, driven by a 9% increase in over-the-counter drugs.
Back in 1989, a court order limited advertising claims for Advil, now owned by Pfizer. But does that order extend to Infants' Advil, which didn't exist at the time? Rival Johnson & Johnson says yes--and it's forced Pfizer to pull one of its ads for that very reason.
Consumers who purchase over-the-counter products like Tylenol online sometimes receive items that are expired, defective, or even counterfeit. Now Johnson & Johnson and Amazon are in a fight over how much the online giant should be doing to keep that from happening.
The FDA has pushed makers of the nonaspirin pain reliever acetaminophen to do more to warn consumers about the dangers of the drug when taken in high doses. J&J is now adding warnings to Tylenol bottle caps in response.
It has been a week of conciliation among some of the Big Pharma players, with Pfizer settling more Chantix litigation, Merck closing out some Vioxx lawsuits and Johnson & Johnson coming to terms with shareholders angered over its handling of Tylenol recalls.
Johnson & Johnson just can't seem to get its consumer health manufacturing in order.
Drugmakers hope to export their success to emerging markets so they can reap big rewards, but Johnson & Johnson's Janssen unit appears to have taken a backward approach in South Korea, where it is in hot water over a recall of Children's Tylenol products.
Johnson & Johnson, whose McNeil Consumer Healthcare is operating under an FDA consent decree, is taking a sales hit this flu season as consumers go to some pharmacies and find few or no Tylenol products on the shelves.
CVS, the drugstore chain, will stop stocking Tylenol in some of its stores. Ongoing supply problems have store shelves still empty, and CVS wants to fill those holes.
Drugmakers, get ready to revise your playbooks. Branded generics may be a no-go in India. Continuing their assault on drug costs, government officials are rolling out a new generics-only licensing policy. New off-patent drugs would win approval under their generic names only.